The significant revenue growth and extended cash runway are positive, but the large net loss, driven by a non-cash accounting item, could pressure the stock. Traders should monitor future clinical trial progress and the potential for additional milestone payments, which could validate the company's technology and drive valuation.
Price Chart
Executive Summary
Lineage Cell Therapeutics reported its 2025 financial results, showing a significant increase in revenue to $14.6 million driven by a milestone payment from its Genentech collaboration, but a wider net loss of $63.5 million due to a $37.9 million non-cash expense from warrant liability revaluation. The company highlighted positive long-term clinical data for its OpRegen therapy, achieved a manufacturing milestone with Genentech, and secured $5.4 million in warrant proceeds, extending its cash runway into Q2 2028.
Key Financial Metrics
Key Facts
- Revenue increased 54% YoY to $14.6 million, primarily from a milestone payment under the Genentech collaboration.
- Net loss widened to $63.5 million from $18.6 million, driven by a $37.9 million non-cash expense for warrant liability revaluation.
- Cash, cash equivalents, and marketable securities totaled $55.8 million as of Dec 31, 2025, with an additional $5.4 million from warrant exercises, funding operations into Q2 2028.
- Achieved the first milestone under its $620 million collaboration with Genentech for the OpRegen cell therapy program.
- Reported positive 36-month clinical data for OpRegen, showing sustained visual acuity gains in patients with geographic atrophy.
Financial Impact
Revenue increased by $5.1 million, but net loss increased by $44.9 million due to a large non-cash expense.
Segment Breakdown
| Segment |
|---|
| OpRegen |
| ReSonance |
Risk Factors
- The large net loss, even if non-cash, could concern investors about the company's path to profitability.
- Future funding may depend on the success of clinical trials and the achievement of further partnership milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-093948 |
| Document: lctx-20260305.htm | 0001193125-26-093948 |
| Document: 0001193125-26-093948-index-headers.html | 0001193125-26-093948 |
| Document: 0001193125-26-093948-index.html | 0001193125-26-093948 |
| Document: 0001193125-26-093948.txt | 0001193125-26-093948 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 12, 2026 23w ago | 8-K | $1.28 $1.28 | · 0.00% | ▲ +0.61% | $1.01 (−20.70%) |
Mar 24, 2026 31w ago | EFFECT | $1.48 $1.63 | ▲ +10.14% | ▲ +1.23% | $1.01 (−31.42%) |
Mar 5, 2026 33w ago | 8-K | $1.85 $1.54 | ▼ −16.76% | ▼ −14.71% | $1.01 (−45.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers